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Supervised learning of microarray data is receiving much attention in recent years. Multiclass cancer diagnosis, based on selected
gene proﬁles, are used as adjunct of clinical diagnosis. However, supervised diagnosis may hinder patient care, add expense or
confound a result. To avoid this misleading, a multiclass cancer diagnosis with class-selective rejection is proposed. It rejects
some patients from one, some, or all classes in order to ensure a higher reliability while reducing time and expense costs.
Moreover, this classiﬁer takes into account asymmetric penalties dependant on each class and on each wrong or partially
correct decision. It is based on ν-1-SVM coupled with its regularization path and minimizes a general loss function deﬁned
in the class-selective rejection scheme. The state of art multiclass algorithms can be considered as a particular case of the
proposed algorithm where the number of decisions is given by the classes and the loss function is deﬁned by the Bayesian
risk. Two experiments are carried out in the Bayesian and the class selective rejection frameworks. Five genes selected datasets
are used to assess the performance of the proposed method. Results are discussed and accuracies are compared with those
computed by the Naive Bayes, Nearest Neighbor, Linear Perceptron, Multilayer Perceptron, and Support Vector Machines
classiﬁers.
Copyright © 2009 Nisrine Jrad et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Cancer diagnosis, based on gene expression proﬁling, have
improved over the past 40 years. Many microarray technolo-
gies studies were developed to analyze the gene expression.
These genes are later used to categorize cancer classes. Two
diﬀerent classiﬁcation approaches can be used: class discov-
eryandclassprediction.Theﬁrstisanunsupervisedlearning
approach that allows to separate samples into clusters based
on similarities in gene expression, without prior knowledge
of sample identity. The second is a supervised approach
which predicts the category of an already deﬁned sample
using its gene expression proﬁles. Since these classiﬁcation
problems are described by a large number of genes and
a small number of samples, it is crucial to perform genes
selection before the classiﬁcation step. One way to identify
informative genes pointed in [1] is the test statistics.
Researches show that the performance of supervised
decisions based on selected gene expression can be com-
parable to the clinical decisions. However, no classiﬁcation
strategy is absolutely accurate. First, many factors may
eﬀectively decrease the predictive power of a multiclass
problem.Forexample,ﬁndingsof[2]implythatinformation
useful for multiclass tumor classiﬁcation is encoded in a
complex gene expression and cannot be given by a simple
one. Second, it is not possible to ﬁnd an optimal classiﬁ-
cation method for all kinds of multiclass problems. Thus,
supervised diagnosis are always considered as an impor-
tant adjunct of traditional diagnostics and never like its
substitute.
Unfortunately, supervised diagnosis can be misleading.
They may hinder patient care (wrong decision on a sick
patient), add expense (wrong decision on a healthy patient)
or confound the results of cancer categories. To overcome2 Journal of Biomedicine and Biotechnology
these limitations, a multi-SVM [3] classiﬁer with class-
selective rejection [4–7] is proposed. Class-selective rejection
consists of rejecting some patients from one, some, or all
classes in order to ensure a higher reliability while reducing
time and expense costs. Moreover, any of the existing
multiclass [8–10] algorithms have taken into consideration
asymmetric penalties on wrong decisions. For example, in a
binary cancer problem, a wrong decision on a sick patient
must cost more than a wrong decision on a healthy patient.
The proposed classiﬁer handles this kind of problems. It
minimizes a general loss function that takes into account
asymmetric penalties dependant on each class and on each
wrong or partially correct decision.
The proposed method divides the multiple class problem
into several unary classiﬁcation problems and train one ν-
1-SVM [11–13] coupled with its regularization path [14,
15] for each class. The winning class or subset of classes
is determined using a prediction function that takes into
consideration the costs asymmetry. The parameters of all
the ν-1-SVMs are optimized jointly in order to minimize a
loss function. Taking advantage of the regularization path
method, the entire parameters searching space is considered.
Since the searching space is widely extended, the selected
decision rule is more likely to be the optimal one. The state-
of-art multiclass algorithms [8–10] can be considered as a
particular case of the proposed algorithm where the number
of decisions is given by the existing classes and the loss
function is deﬁned by the Bayesian risk.
Two experiments are reported in order to assess the per-
formance of the proposed approach. The ﬁrst one considers
the proposed algorithm in the Bayesian framework and uses
the selected microarray genes to make results comparable
with existing ones. Performances are compared with those
assessed using Naive Bayes, Nearest Neighbor, Linear Percep-
tron, Multilayer Perceptron, and Support Vector Machines
classiﬁers,invokedin[1].Thesecondoneshowstheabilityof
the proposed algorithm solving multiclass cancer diagnosis
in the class-selective rejection scheme. It minimizes an
asymmetric loss function. Experimental results show that,
a cascade of class-selective classiﬁers with class-selective
rejections can be considered as an improved supervised
diagnosis rule.
This paper is outlined as follows. Section 2 presents
a description of the model as a gene selection task. It
introduces the multiclass cancer diagnosis problem in the
class-selective rejection scheme. It also proposes a supervised
training algorithm based on ν-1-SVM coupled with its
regularization path. The two experiments are carried out
in Section 3, results are reported, compared and discussed.
Finally, a conclusion is presented in Section 4.
2.Models andMethods
This section describes the multiclass cancer diagnosis based
on microarray data. Feature selection is evoked as a ﬁrst
process in a gene-based cancer diagnosis. Test statistics are
used as a possible way for informative genes identiﬁcation
[1]. Once genes selection is processed, a classiﬁcation
problem should be solved. The multiclass cancer diagnosis
problem, formulated in the general framework of class-
selective rejection, is introduced. A solution based on ν-1-
SVM [11–13] is proposed. First a brief description of ν-1-
SVM and the derivation of its regularization path [14, 15]i s
presented. Second, the proposed algorithm [3] is explained.
It allows to determine a multiclass cancer diagnosis that
minimizes an asymmetric loss function in the class-selective
rejection scheme.
2.1. Genes Selection Using Test Statistics. Gene proﬁles are
successfully applied to supervised cancer diagnosis. Since
cancer diagnosis problems are usually described by a small
set of samples with a large number of genes, feature or
gene selection is an important issue in analyzing multiclass
microarray data. Given a microarray data with N tumor
classes, n tumor samples and g genes per sample, one
should identify a small subset of informative genes that
contribute most to the prediction task. Various feature
selection methods exist in literature. One way pointed in [1]
is to use test statistics for the equality of the class means.
Authors of [1] formulate ﬁrst the expression levels of a given
gene by a one-way analysis of variance model. Second, the
power of genes in discriminating between tumor types is
determinedbyateststatistic.Thediscriminationpoweristhe
value of the test evaluated at the expression level of the gene.
The higher the discrimination power is, the more powerful
the gene is in discriminating between tumor types. Thus,
genes with higher power of discrimination are considered as
informative genes.
Let Yjpbe the expression level fromthe pth sample of the
jth class, the following general model is considered:
Yjp=μj + jp for j=1,...,N; p=1,...,nj with
N 
j=1
nj =n.
(1)
In the model μj represents the mean expression level of the
gene in class wj, jp are independent random variables and
E(jp) = 0, V(jp) = σ2
j < ∞ for j = 1,...,N; p = 1,...,nj.
For the case of homogeneity of variances, the ANOVA F
or F test [16] is the optimal one testing the means equality
hypothesis. With heterogeneity of variances, the task is
challenging. However, it is known that, with a large number
of genes present, usually in thousands, no practical test is
available to locate the best set of genes. Thus, the authors of
[1] studied six diﬀerent statistics.
(i) ANOVA F test statistic, the deﬁnition of this test is
F =
(n −N)

nj

Yj· −Y··
2
(N −1)

nj −1

s2
j
,( 2 )
where Yj· =
nj
p=1Yjp/nj and Y·· =
N
j=1njYj·/n,
s2
j =
nj
p=1(Yjp− Yj·)
2/(nj − 1). For simplicity,

is used to indicate the sum taken over the index
j. Under means equality hypothesis and assuming
variance homogeneity, this test has a distribution of
FN−1,n−N [16].Journal of Biomedicine and Biotechnology 3
(ii) Brown-Forsythe test statistic [17], given by
B =

nj

Yj· −Y··
2

1 − nj/n

s2
j
. (3)
Under means equality hypothesis, B is distributed
approximately as FN−1,τ where
τ =

(1 −nj/n)s2
j
2

1 −nj/n
2
s4
j/

nj −1
. (4)
(iii) Welch test statistic [18], deﬁned as
W =

ωj

Yj· −

hjYj·
2
(N −1)+2 (N −2)(N +1 )
−1 
nj −1
−1
1 −hj
2,
(5)
with ωj = nj/s2
j and hj = ωj/

ωj.U n d e r
means equality hypothesis, W has an approximate
distribution of FN−1,τω where
τω =
N2 −1
3

nj −1
−1
1 −hj
2. (6)
(iv) Adjusted Welch test statistic [19]. It is similar to
Welch statistic and deﬁned to be
W∗ =

ω
∗
j

Yj· −

h
∗
j Yj·
2
(N−1)+2(N−2)(N+1)
−1 
nj−1
−1
1 − h
∗
j
2,
(7)
where ω
∗
j = nj/(Φjs2
j)w i t hΦj chosen such that 1 ≤
Φj ≤ (nj − 1)/(nj − 3) and h
∗
j = ω
∗
j /

ω
∗
j .U n d e r
means equality hypothesis, W∗ has an approximate
distribution of FN−1,τ∗
ω where
τ
∗
ω =
N2 −1
3

nj −1
−1
1 −h
∗
j
2. (8)
(v) Cochran test statistic [20]. This test statistic is simply
thequantityappearinginthenumeratoroftheWelch
test statistic W, that is,
C =

ωj

Yj· −

hjYj·
2
. (9)
Under means equality hypothesis, C has an approxi-
mate distribution of χ2
N−1.
(vi) Kruskal-Wallis test statistic. This is the well-known
nonparametric test given by
H =
12
n(n+1 )
 R2
j
nj
− 3(n+1 ), (10)
where Rj is the rank sum for the jth class. The ranks
assigned to Yjp are those obtained from ranking the
entire set of Yjp. Assuming each nj ≥ 5, then under
means equality hypothesis, H has an approximate
distribution of χ2
N−1 [21].
These tests performances are evaluated and compared
over diﬀerent supervised learning methods applied to pub-
liclyavailablemicroarraydatasets.Experimentalresultsshow
that the model for gene expression values without assuming
equalvariancesismoreappropriatethanthatassumingequal
variances. Besides, under heterogeneity of variances, Brown-
Forsythe test statistic, Welch test statistic, adjusted Welch test
statistic,andCochranteststatistic,performmuchbetterthan
ANOVA F test statistic and Kruskal-Wallis test statistic.
2.2. Multitumor Classes with Selective Rejection. Once gene
selection is processed, the classiﬁcation problem should be
solved. Let us deﬁne this diagnosis problem in the class-
selective rejection scheme. Assuming that the multiclass
cancer problem deals with N tumor classes noted w1...w N
and that any patient or sample x belongs to one tumor class
and has d informative genes, a decision rule consists in a
partition Z of Rd in I sets Zi corresponding to the diﬀerent
decision options. In the simple classiﬁcation scheme, the
options are deﬁned by the N tumor classes. In the class-
selective rejection scheme, the options are deﬁned by the N
tumor classes and the subsets of tumor classes (i.e. assigning
patient x to the subset of tumor classes {w1,w3} means that
x is assigned to cancer categories w1 and w3 with ambiguity).
The problem consists in ﬁnding the decision rule Z∗ that
minimizes a given loss function c(Z)d e ﬁ n e db y
c(Z) =
I 
i=1
N 
j=1
cijPjP

Di/wj

, (11)
wherecij isthecostofassigningapatientx totheithdecision
option when it belongs to the tumor class wj.T h ev a l u e s
of cij being relative since the aim is to minimize c(Z), the
values can be deﬁned in the interval [0;1] without loss of
generality. Pj is the a priori probability of tumor class wj and
P(Di/wj)istheprobabilitythatpatientsofthetumorclasswj
are assigned to the ith option.
2.3. μ-1-SVM. To solve the multiclass diagnosis problem, an
approach based on ν-1-SVM is proposed. Considering a set
of m samples of a given tumor classes X ={ x1,x2,...,xm}
drawnfromaninputspaceX,ν-1-SVMcomputesadecision
function f λ
X(·)a n dar e a ln u m b e rbλ in order to determine
the region Rλ in X such that f λ
X(x) − bλ ≥ 0 if the sample
x ∈ Rλ and f λ
X(x) −bλ < 0 otherwise. The decision function
f λ
X(·) is parameterized by λ = νm (with 0 ≤ ν < 1) to
control the number of outliers. It is designed by minimizing
the volume of Rλ under the constraint that all the samples
of X, except the fraction ν of outliers, must lie in Rλ.I n
o r d e rt od e t e r m i n eRλ, the space of possible functions f λ
X(·)
is reduced to a Reproducing Kernel Hilbert Space (RKHS)
withkernelfunctionK(·,·).LetΦ : X → H bethemapping
deﬁned over the input space X.L e t ·,· H be a dot product
deﬁned in H.T h ek e r n e lK(·,·)o v e rX ×X is deﬁned by:
∀

xp,xq

∈ X × X K

xp,xq

=

Φ

xp

,Φ

xq
	
H.
(12)4 Journal of Biomedicine and Biotechnology
Without loss of generality, K(·,·) is supposed normalized
such that for any x ∈ X, K(x,x) = 1. Thus, all the mapped
vectors Φ(xp), p = 1,...,m are in a subset of a hypersphere
with radius one and center O.P r o v i d e dK(·,·)i sa l w a y s
positive and Φ(X) is a subset of the positive orthant of the
hypersphere. A common choice of K(·,·) is the Gaussian
RBF kernel K(xp,xq) = exp[−1/2σ2 xp −xq 
2
X]w i t hσ the
parameter of the Gaussian RBF kernel. ν-1-SVM consists of
separating the mapped samples in H from the center O with
ah y p e r p l a n eWλ. Finding the hyperplane Wλ is equivalent
to ﬁnd the decision function f λ
X(·) such that f λ
X(x) − bλ =
 wλ,Φ(x) H −bλ ≥ 0 forthe (1−ν)mmappedsampleswhile
Wλ isthehyperplanewithmaximummarginbλ/ wλ H with
wλ the normal vector of Wλ.
This yields f λ
X(·) as the solution of the following convex
quadratic optimization problem:
min
wλ,bλ,ξp
m 
p=1
ξp −λbλ +
λ
2

 
 
wλ

 
 

2
H
subject to

wλ,Φ

xp
	
H≥bλ −ξp, ξp≥∀ p=1,...,m
(13)
where ξp are the slack variables. This optimization problem
is solved by introducing lagrange multipliers αp.A sa
consequence to Kuhn-T¨ ucker conditions, wλ is given by
wλ =
1
λ
m 
p=1
αpΦ

xp

, (14)
which results in
f λ
X(·) −bλ =
1
λ
m 
p=1
αpK

xp,·

−bλ. (15)
The dual formulation of (13) is obtained by introducing
Lagrange multipliers as
min
α1,...,αm
1
2λ
m 
p=1
m 
q=1
αλ
pαλ
qK

xp,xq

with
m 
p=1
αλ
p = λ,0 ≤ αλ
p ≤ 1 ∀p = 1,...,m.
(16)
A geometrical interpretation of the solution in the RKHS
is given by Figure 1. f λ
X(·)a n dbλ deﬁne a hyperplane
Wλ orthogonal to f λ
X(·). The hyperplane Wλ separates the
Φ(xp)s from the sphere center, while having bλ/ wλ H
maximum which is equivalent to minimize the portion Sλ
of the hypersphere bounded by Wλ that contains the set
{Φ(x)s .t.x∈ Rλ}.
Tuning ν or equivalently λ is a crucial point since it
enables to control the margin error. It is obvious that chang-
ing λ leads to solve the optimization problem formulated in
(16) in order to ﬁnd the new region Rλ. To obtain great
computational savings and extend the search space of λ,
we proposed to use ν-1-SVM regularization path [14, 15].
Regularization path was ﬁrst introduced by Hastie et al.
[14] for a binary SVM. Later, Rakotomamojy and Davy [15]
developed the entire regularization path for a ν-1-SVM. The
basic idea of the ν-1-SVM regularization path is that the
p a r a m e t e rv e c t o ro faν-1-SVM is a piecewise linear function
of λ. Thus the principle of the method is to start with large λ,
(i.e., λ = m − ) and decrease it towards zero, keeping track
of breaks that occur as λ varies.
As λ decreases,  wλ H increases and hence the distance
between the sphere center and Wλ decreases. Samples move
from being outside (non-margin SVs with αλ
p = 1i n
Figure 1) to inside the portion Sλ (non-SVs with αλ
p = 0).
By continuity, patients must linger on the hyperplane Wλ
(margin SVs with 0 <α λ
p < 1) while their αλ
psd e c r e a s e
f r o m1t o0 .αλ
ps are piecewise-linear in λ. Break points occur
when a point moves from a position to another one. Since
αλ
p is piecewise-linear in λ, f λ(·)a n dbλ are also piecewise-
linear in λ. Thus, after initializing the regularization path
(computing αλ
p by solving (16)f o rλ = m − ), almost all the
αλ
ps are computed by solving linear systems. Only for some
few integer values of λ smaller than m, αλ
psa r ec o m p u t e db y
solving (16) according to [15].
Using simple linear interpolation, this algorithm enables
to determine very rapidly the ν-1-SVM corresponding to any
value of λ.
2.4. Multiclass SVM Based on μ-1-SVM. Given N classes
and N trained ν-1-SVMs, one should design a supervised
decision rule Z, moving from unary to multiclass classiﬁer
by assigning samples to a decision option. To determine
the decision rule, ﬁrst a prediction function should decide
the winning option. A distance measure between x and the
training class set wj, using the ν-1-SVM parameterized by λj,
is deﬁned as follows:
dλj(x) =
cos

 wλj,Φ(x)

cos

θλj
 =

 
 
wλj

 
 

H
bλj cos

 wλj,Φ(x)

,
(17)
whereθλj istheangledelimitedbywλj andthesupportvector
as shown in Figure 1.c o s ( θλj) is a normalizing factor which
is used to make all the dλ
j(x)c o m p a r a b l e .
Using  Φ(x) =1i n( 17) leads to the following:
dλj(x) =

wλj,Φ(x)
	
H
bλj =
1/λj
nj
p=1α
λj
p K

xp,x

bλj . (18)
Since the α
λj
p are obtained by the regularization path for
any value of λj, computing dλj is considered as an easy-
fast task. The distance measure dλj(x) is inspired from [22].
When data are distributed in a unimodal form, the dλj(x)i s
a decreasing function with respect to the distance between
as a m p l ex and the data mean. The probability density
function is also a decreasing function with respect to the
distance from the mean. Thus, dλj(x) preserves distribution
order relations. In such case, and under optimality of the
ν-1-SVM classiﬁer, the use of dλj(x) should reach the same
performances as the one obtained using the distribution.Journal of Biomedicine and Biotechnology 5
Non-margin SV
Wλ
O
R = 1 θλ bλ
||wλ||H
Margin SV
Non-SVs
Sλ
wλ
Figure 1: Training data mapped into the feature space on a portion
Sλ of a hypersphere.
In the simplest case of multiclass problems where the loss
function is deﬁned as the error probability, a patient x is
assigned to the tumor class maximizing dλj(x).
To extend the multiclass prediction process to the class-
selective scheme, a weighted form of the distance measure
is proposed. The weight βj is associated to dλj. βj reﬂects
an adjusted value of the distance dλj according to the
penaltyassociatedwiththetumorclasswj.Thus,introducing
weights leads to treat diﬀerently each tumor class and helps
solving problems with diﬀerent costs cij on the classiﬁcation
decisions.
Finally, in the general case where the loss function
is considered in the class-selective rejection scheme, the
prediction process can be deﬁned as follows: a blinded
sample x is assigned to the ith option if and only if
N 
j=1
cijPjβjdλj(x) ≤
N 
j=1
cljPjβjdλj(x), ∀l = 1...I, l / =i.
(19)
Thus, in contrast to previous multiclass SVMs, which
construct the maximum margin between classes and locate
the decision hyperplane in the middle of the margin, the
proposed approach resembles more to the robust Bayesian
classiﬁer. The distribution of each tumor class is considered
and the optimal decision is slightly deviated toward the class
with the smaller variance.
Theproposeddecisionruledependsonσ,ν andβ vectors
of σj, νj and βj for j = 1,...,N. Tuning νj is the most
time expensive task since changing νj leads to solve the
optimization problem formulated in (16). Moreover, tuning
νj is a crucial point, it enables to control the margin error. In
fact, it was shown in [11] that this regularization parameter
is an upper bound on the fraction of outliers and a lower
bound on the fraction of the SVs. In [9, 23]as m o o t hg r i d
search was supplied in order to choose the optimal values
of ν.T h eN values νjs were chosen equal to reduce the
computational costs. However, this assumption reduces the
search space of parameters too. To avoid this restriction, the
proposed approach optimizes all the νj with j = 1,...,N
corresponding to the Nν-1-SVMs using regularization path
and consequently explores the entire parameters space. Thus
the tuned νj are most likely to be the optimal ones. The
parameter σ are set equals σ1 = σ2 =···=σN.
The optimal vector of σj, λj and βj, j = 1,...,N, is the
one which minimizes an estimator of c(Z) using a validation
set. Since the problem is described by a sample set, an
estimator 
 c(Z)o fc(Z)g i v e nb y( 11)i su s e d :

 c(Z) =
I 
i=1
N 
j=1
cij
 Pj 
 P

Di
wj

, (20)
where 
 Pj and 
 P(Di/wj)aretheempiricalestimatorsofPj and
P(Di/wj), respectively.
The optimal rule is obtained by tuning λj, βj and σj so
that the estimated loss 
 c(Z) computed on a validation set
is minimum. This is accomplished by employing a global
search for λj and βj and an iterative search over the kernel
parameter. For each given value σ of the parameter kernels,
ν-1-SVMs are trained using the regularization path method
on a training set. Then the minimization of 
 c(Z)o v e ra
validation set is sought by solving an alternate optimization
problem over λj and βj which is easy since all ν-1-SVM
solutionsareeasilyinterpolatedfromtheregularizationpath.
σ is chosen from a previously deﬁned set of real numbers
[σ0,...,σs]w i t hs ∈ℵ . Algorithm 1 elucidates the proposed
approach.
3. ExperimentalResults
I nt h i ss e c t i o n ,t w oe x p e r i m e n t sa r er e p o r t e di no r d e rt o
assess the performance of the proposed approach. First, the
cancer diagnosis problem is considered in the traditional
Bayesian framework. Five gene expression datasets and ﬁve
supervised algorithms are considered. Each gene dataset was
selected using the six test statistics of [1]. The decisions
are given by the possible set of tumor classes and the loss
function is deﬁned as the probability of error to make results
comparable with those of [1]. Second, in order to show the
advantages of considering the multiclass cancer diagnosis
in class-selective rejection scheme, one gene dataset is
considered and studied with an asymmetric loss function. A
cascade of classiﬁers with rejection options is used to ensure
a reliable diagnosis. For both experiments, the loss function
was minimized by determining the optimal parameters βj
and λj for j = 1,...,N for a given kernel parameter σ and by
testingdiﬀerentvaluesofσ intheset[2−3,2 −2,2 −1,2 0,2 1,2 2].
Finally, the decision rule which minimizes the loss function
is selected.
3.1. Bayesian Framework. Five multiclass gene expression
datasets leukemia72 [24], ovarian [25], NCI [26, 27], lung
cancer [28] and lymphoma [29]w e r ec o n s i d e r e d .Table 1
describes the ﬁve genes datasets. For each dataset, the six
test statistics F, B, W, W∗, C,a n dH were used to select
informative genes.
The cancer diagnosis problem was considered in the
traditional Bayesian framework. Decisions were given by the
set of possible classes and loss function was deﬁned by the
error risk. This means that in (20) cij are deﬁned according6 Journal of Biomedicine and Biotechnology
1 θ :=∅
2 C :=∅
3f o rσ ← σ0 to σs do
4 /∗UsingtheTrainingSet∗/
5f o r j ← 1t oN do
6T r a i n ν-1-SVM on wj,n a m e l ys o l v i n gt h eQ P( 16)
7 Derive the regularization path for wj, namely compute the αλjs
8e n d
9 /∗UsingtheValidation Set∗/
10 λ := λ0
11 β := β0
12 repeat
13 dλj(x): =
1
λj
nj
p=1α
λj
p K(xp,x)/bλj
14 
 Pj :=| wj|/
N
j=1|wj| /∗|| = cardinality∗/
15 Assign x to a decision ψi according to (19)
16 
 P(Di/wj): =| { x of wj assigned to ψi}|/|{x/x ∈ wj}|
17 
 c(Z): =
I
i=1
N
j=1cij
 Pj 
 P(Di/wj)
18 λ := λnew/∗ construct the new vector according to the
direction of greatest decrease ∗/
19 β := βnew
20 until 
 c(Z)is minimum
21 θ := θ ∪{σ,λ,β}
22 C := C ∪{
 c(Z)}
23 end
24 index := min{C}
25 θoptimal := θindex
Algorithm 1: Multiclass SVM minimizing an asymmetric loss function.
Table 1: Multiclass gene expression datasets.
Dataset Leukemia72 Ovarian NCI Lung
cancer
Lymphoma
No. of gene 6817 7129 9703 918 4026
No. of sample 72 39 60 73 96
No. of class 3 3 9 7 9
Table 2: Loss function cost matrix in the Bayesian framework.
Patient class
12 . .N
101 ·· 1
210 1 ·
Prediction ··· · ··
·· · ·1
N 1 ··10
to the Table 2. The performance of the proposed method
was measured by evaluating its accuracy rate and it was
compared to results obtained by the ﬁve predictors evoked
in [1]: Naive Bayes, Nearest Neighbor, Linear Perceptron,
Multilayer Perceptron Neural Network with ﬁve nodes in
the middle layer, and Support Vector Machines with second-
order polynomial kernel.
To compute the generalization accuracy of the proposed
classiﬁer, Leave One Out (LOO) resampling method is used
to divide a gene dataset of n patients into two sets, a set
of n − 1 patients and a test set of 1 blinded patient. This
method involves n separate runs. For each run, the ﬁrst set
of n − 1 samples is divided using 5 Cross-validation (5-
CV) into a training set and a validation set. Nν-1-SVMs
are trained using the training set for all values of νj.T h e
decision is obtained by tuning the parameters βj, λj and
σj for j = 1,...,N so that the loss function computed
on the validation set is minimum. Optimal parameters are
then used to build the decision rule using the whole n − 1
samples. The blinded test set is classiﬁed according to this
rule. The overall prediction error is the sum of the patients
misclassiﬁed on all n runs.
Table 3 reports errors of the proposed algorithm, the
average value and the median value of the 5 classiﬁers
prediction errors reported in [1] when 50 informative genes
are used. Table 4 reports values when 100 informative genes
are used. F, B, W, W∗, C,a n dH represent the six test
statistics.
Experimental results show that, for ovarian, NCI, lung
cancer and lymphoma multiclass genes problems, the pro-
posed approach achieves competitive performances com-
pared to the 5 classiﬁers reported in [1]. For these datasets,
prediction errors of the proposed approach are less than the
mean and median values of the 5 classiﬁers prediction errors
reported in [1]. However, for leukemia72, the proposedJournal of Biomedicine and Biotechnology 7
Table 3: Prediction errors of the proposed classiﬁer, mean and median values of the 5 classiﬁers prediction errors according to [1] with 50
informative selected genes.
FB W W ∗ CH
Leukemia
P r o p o s e d a l g o r i t h m 435532
Mean 3.4 2.4 2.8 2.8 3.2 3.0
M e d i a n 323333
Ovarian
P r o p o s e d a l g o r i t h m 000000
Mean 0.2 0.0 0.0 0.0 0.0 0.0
M e d i a n 000000
NCI
P r o p o s e d a l g o r i t h m 3 12 62 72 72 73 3
Mean 36.0 32.0 27.4 26.0 27.0 35.4
M e d i a n 3 52 92 72 72 73 5
Lung cancer
P r o p o s e d a l g o r i t h m 1 41 61 61 61 61 5
Mean 17.6 17.0 17.6 17.6 18.0 18.0
M e d i a n 1 71 71 81 81 81 8
Lymphoma
P r o p o s e d a l g o r i t h m 1 8 1 691 091 5
Mean 23.8 19.8 14.0 14.0 12.8 22.0
M e d i a n 2 31 91 21 21 32 0
Table 4: Prediction errors of the proposed classiﬁer, mean and median values of the 5 classiﬁers prediction errors according to [1] with 100
informative selected genes.
FB W W ∗ CH
Leukemia
P r o p o s e d a l g o r i t h m 523346
Mean 3.4 3.0 3.0 3.0 3.2 3.0
M e d i a n 334333
Ovarian
P r o p o s e d a l g o r i t h m 000000
Mean 0.2 0.0 0.0 0.0 0.0 0.0
M e d i a n 000000
NCI
P r o p o s e d a l g o r i t h m 3 32 12 62 52 63 6
Mean 33.0 22.6 23.8 25.2 25.2 31.6
M e d i a n 3 32 22 52 62 63 1
Lung cancer
P r o p o s e d a l g o r i t h m 1 11 01 11 11 11 3
Mean 12.2 12.2 11.4 12.2 12.2 15.8
M e d i a n 1 21 21 11 11 11 4
Lymphoma
P r o p o s e d a l g o r i t h m 1 61 61 11 01 11 7
Mean 21.8 19.2 13.0 13.8 14.4 18.2
M e d i a n 1 71 61 21 21 21 8
Table 5: Confusion matrix of 50 W∗ lung cancer dataset. Total of
misclassiﬁed is equal to 16.
Patient class
Normal SCLC LCLC SCC AC2 AC3 AC1
Predicted
decision
Normal 6 0 0 0 0 0 0
SCLC 0 4 0 0 0 1 0
LCLC 0 0 3 0 0 4 1
SCC 0 0 0 16 0 3 0
AC2 0 0 0 0 4 0 0
AC3 0 1 1 0 1 4 0
AC1 0 0 1 0 2 1 20
Table 6: Confusion Matrix of 50H lung cancer dataset. Total of
misclassiﬁed is equal to 15.
Patient class
Normal SCLC LCLC SCC AC2 AC3 AC1
Predicted
decision
Normal 5 0 0 0 0 0 0
SCLC 0 4 0 0 0 0 0
LCLC 0 0 1 1 0 2 2
SCC 0 0 2 14 0 1 0
AC2 0 0 0 0 7 0 0
AC3 0 0 2 1 0 8 0
AC1 1 1 0 0 0 2 198 Journal of Biomedicine and Biotechnology
Table 7: Asymmetric cost matrix of the loss function.
Patient class
Normal SCLC LCLC SCC AC2 AC3 AC1
N o r m a l 0 1 1 1111
S C L C 1 0 1 1111
LCLC 1 1 0 0.9 0.9 1 1
SCC 1 1 0.9 0 0.9 1 0.9
AC2 1 1 0.9 0.9 0 0.9 0.9
Predicted
decision
AC3 1 1 0.9 0.9 0.9 0 0.9
AC1 1 1 0.9 0.9 0.9 0.9 0
{LCLC, SCC, AC3} 1 1 0.6 0.6 0.9 0.2 0.9
All tumors 1 0.2 0.6 0.6 0.2 0.2 0.5
All classes 0.6 0.2 0.6 0.6 0.2 0.6 0.6
Table 8: Confusion matrix of the 50 W∗ lung cancer problem with class-selective rejection using cost matrix deﬁned in Table 7.T o t a lo f
misclassiﬁed is equal to 10, total of partially and totally rejected samples is equal to 8.
Patient class
Normal SCLC LCLC SCC AC2 AC3 AC1
N o r m a l 6 0 0 0000
S C L C 0 3 0 0000
LCLC 0 0 3 0 0 4 0
SCC 0 0 0 16 0 2 0
Predicted
decision
A C 2 0 0 0 0400
A C 3 0 0 0 0130
AC1 0 0 1 0 1 1 20
{LCLC, SCC, AC3} 0 0 1 0020
A l l t u m o r s 0 2 0 0111
All classes 0 0 0 0 0 0 0
algorithm performances are almost in the same range of
those provided by the 5 classiﬁers reported in [1]. The
proposed approach prediction error is equal, or in the worst
case, slightly higher than the mean and median errors.
Moreover, we can note that focussing on the test statistics
comparison, experimental results conﬁrm those of [1]. B, W
and W∗ can be the most performing tests under variances
heterogeneity assumptions.
3.2. Class-Selective Rejection Framework. In the following,
we present the study of lung cancer problem in the class-
selective rejection scheme. Lung cancer diagnosis problem is
determined bythegeneexpression proﬁlesof67lung tumors
and 6 normal lung specimens from patients whose clinical
course was followed for up to 5 years. The tumors comprised
41 Adenocarcinomas (ACs), 16 squamous cell carcinomas
(SCCs); 5 cell lung cancers (LCLCs) and 5 small cell lung
cancers (SCLCs). ACs are subdivided into three subgroups
21 AC of group 1 tumors, 7 AC of group 2 tumors and 13
AC of group 3 tumors. Thus, the multiclass diagnosis cancer
consists of 7 classes.
Authors in [28]o b s e r v e dt h a tA Co fg r o u p3t u m o r s
shared strong expression of genes with LCLC and SCC
tumors. Thus, poorly diﬀerentiated AC is diﬃcult to dis-
tinguish from LCLC or SCC. Confusion matrices (Tables 5
and 6) computed in the Bayesian framework, with 50W∗
and 50H prove well these claims. It can be noticed that
8 of the 16 misclassiﬁed 50W∗ patients and 8 of the 15
misclassiﬁed 50H patients correspond to confusion between
these three subcategories. Therefore, one may deﬁne a new
decision option as a subset of these three classes to reduce
error.
Moreover, same researches aﬃrm that distinction
between patients with nonsmall cell lung tumors (SCC, AC
and LCLC) and those with small cell tumors or SCLC is
extremely important, since they are treated very diﬀerently.
Thus, a confusion or wrong decision among patients of
nonsmall cell lung tumors should cost less than a confusion
between nonsmall and small lung cells tumors. Besides, one
may provide an extra decision option that includes all the
subcategories of tumors to avoid this kind of confusion.
Finally, another natural decision option can be the set of allJournal of Biomedicine and Biotechnology 9
Table 9: Confusion matrix of the cascade classiﬁer (50W∗ with rejection and 50H classiﬁer). Total of misclassiﬁed is equal to 13.
Patient class
Normal SCLC LCLC SCC AC2 AC3 AC1
Predicted
decision
N o r m a l6 0 0 0000
S C L C 0 4 0 0000
LCLC 0 0 3 0 0 4 1
SCC 0 0 0 16 0 2 0
A C 2 0 0 0 0500
A C 3 0 1 1 0160
AC1 0 0 1 0 1 1 20
classes, which means that the classiﬁer has totally withhold
taking a solution.
Given all these information, the loss function can be
empirically deﬁned according to the asymmetric cost matrix
given in Table 7. Solving 50W∗ lung cancer problem in
this scheme leads to the confusion matrix presented in
Table 8.A sac o m p a r i s o nw i t hTable 5, one may mainly note
that the number of misclassiﬁed patients decreases from 16
to 10 and 8 withhold decisions or rejected patients. This
partial rejection contributes to avoid confusion between
nonsmall and small lung cells tumors and reduces errors
due to indistinctness among LCLC, SCC and AC3. Besides,
according to the example under study, no patient is totally
rejected. It is an expected result since initially (Table 5) there
was no confusion between normal and tumor samples.
To take a decision concerning the rejected patients,
we may refer to clinical analysis. It is worth to note that
for partially rejected patients, clinical analysis will be less
expensive in terms of time and money than those on
completely blinded patients. Moreover, a supervised solution
c a nb ea l s op r o p o s e d .I ta i m st ou s eg e n e ss e l e c t e df r o m
another test statistic in order to assign rejected patients to
one of the possible classes. According to Tables 3 and 4,
prediction errors computed on same patients using genes
selectedbydiﬀerentteststatisticsmaydecreasesinceerrorsof
two diﬀerent test statistics do not occur on the same patients.
Thus, we chose 50H lung cancer dataset to reclassify the
8 rejected patients of Table 8. Five of them were correctly
classiﬁed while three remained misclassiﬁed. Results are
reported in Table 9. The number of misclassiﬁed patients
decreases to 13 which is less than all the prediction errors
obtained with 50 informative genes (lung cancer problem
prediction errors of Table 3). In fact, many factors play an
important role in the cascade classiﬁers system such as the
asymmetric costs matrix which has been chosen empirically,
the choice of test statistics, the number of classiﬁers in a
cascade system,.... Such concerns are under study.
4. Conclusion
Cancer diagnosis using genes involve a gene selection task
and a supervised classiﬁcation procedure. This paper tackles
the classiﬁcation step. It considers the problem of gene-based
multiclass cancer diagnosis in the general framework of
class-selective rejection. It gives a general formulation of the
problem and proposes a possible solution based on ν-1-SVM
coupled with its regularization path. The proposed classiﬁer
minimizes any asymmetric loss function. Experimental
results show that, in the particular case where decisions
are given by the possible classes and the loss function
is set equal to the error rate, the proposed algorithm,
compared with the state of art multiclass algorithms, can
be considered as a competitive one. In the class-selective
rejection, the proposed classiﬁer ensures higher reliability
and reduces time and expense costs by introducing partial
and total rejection. Furthermore, results prove that a cascade
of classiﬁers with class-selective rejections can be considered
a sag o o dw a yt og e ti m p r o v e ds u p e r v i s e dd i a g n o s i s .T og e t
the most reliable diagnosis, the confusion matrix deﬁning
the loss function should be carefully chosen. Finding the
optimal loss function according to performance constraints
is an promising approach [30] which is actually under
investigation.
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